First Patient Reaches Four Years in DMX-200 Clinical Program

Key points

• First patient completes four years in DMX-200 clinical program
• Significant milestone achieved with sustained patient engagement
• High participation rate in the Open Label Extension study

Full summary

Dimerix Limited, a clinical-stage biopharmaceutical company, announced that the first patient has successfully completed four years of participation in the DMX-200 clinical development program for focal segmental glomerulosclerosis (FSGS). The milestone includes completion of the two-year ACTION3 Phase 3 trial and the two-year Open Label Extension (OLE) study. Over 90% of eligible patients who completed the ACTION3 trial have elected to continue into the OLE study, reflecting strong commitment from patients and investigators. The OLE study provides additional long-term safety and efficacy data for DMX-200, which may support future regulatory and commercial activities. Dimerix also plans to offer continued access to DMX-200 through a post-trial access program pending ethics approval.